Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
Journal of Endocrinological Investigation
|
October 22, 2021
SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people
A D Fisher, G Senofonte, C Cocchetti, et al.
Journal of Endocrinological Investigation
|
July 2, 2022
Apparent autistic traits in transgender people: a prospective study of the impact of gender-affirming hormonal treatment
F Mazzoli, E Cassioli, J Ristori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial
M Rinaldi, L Crinò, G V Scagliotti, et al.
Breast Cancer Research and Treatment
|
October 24, 2003
Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients
V Ludovini, A Sidoni, L Pistola, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2002
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study
M Colozza, G Bisagni, A M Mosconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study
L Crinò, G Scagliotti, M Marangolo, et al.
The Oncologist
|
December 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25
Coline Montégut, Claire Falandry, Saverio Cinieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 23, 2022
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
S I Labidi-Galy, M Rodrigues, J L Sandoval, et al.
The Lancet. Oncology
|
April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Sandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
Journal of Endocrinological Investigation
|
May 11, 2024
Sociodemographic profile, health-related behaviours and experiences of healthcare access in Italian transgender and gender diverse adult population
M Marconi, M T Pagano, J Ristori, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
Journal of Endocrinological Investigation
|
October 22, 2021
SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people
A D Fisher, G Senofonte, C Cocchetti, et al.
Journal of Endocrinological Investigation
|
July 2, 2022
Apparent autistic traits in transgender people: a prospective study of the impact of gender-affirming hormonal treatment
F Mazzoli, E Cassioli, J Ristori, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 6, 2000
A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial
M Rinaldi, L Crinò, G V Scagliotti, et al.
Breast Cancer Research and Treatment
|
October 24, 2003
Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients
V Ludovini, A Sidoni, L Pistola, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 21, 2002
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study
M Colozza, G Bisagni, A M Mosconi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 1, 1997
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study
L Crinò, G Scagliotti, M Marangolo, et al.
The Oncologist
|
December 14, 2024
Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25
Coline Montégut, Claire Falandry, Saverio Cinieri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 23, 2022
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis
S I Labidi-Galy, M Rodrigues, J L Sandoval, et al.
The Lancet. Oncology
|
April 18, 2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Sandro Pignata, Domenica Lorusso, Giovanni Scambia, et al.
Journal of Endocrinological Investigation
|
May 11, 2024
Sociodemographic profile, health-related behaviours and experiences of healthcare access in Italian transgender and gender diverse adult population
M Marconi, M T Pagano, J Ristori, et al.
Page
of 6